Results 91 to 100 of about 4,766 (189)

Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.

PLoS ONE, 2013
Most studies describing phenotypic resistance to integrase strand transfer inhibitors have analyzed viruses carrying only patient-derived HIV-1 integrase genes (INT-recombinant viruses).
Jan Weber, Justine D Rose, Ana C Vazquez, Dane Winner, Nicolas Margot, Damian J McColl, Michael D Miller, Miguel E Quiñones-Mateu   +7 more
doaj   +1 more source

Kinetic Characterization of elvitegravir (EVG) in the presence and absence of cobicistat (COBI) and/or ethanol (EtOH)

, 2016
Kinetic Characterization of elvitegravir (EVG) in the presence and absence of cobicistat (COBI) and/or ethanol (EtOH)
Mohammad A. Rahman (1806823), Chetan Rathi (1806826), Weihua Li (144468), Santosh Kumar (106550), Bernd Meibohm (110267), Junhao Li (844050), Narasimha M. Midde (309014)   +6 more
core  

UPLC SEPARATION ANALYSIS OF EMTRICITABINE, TENOFOVIR, COBICISTAT AND ELVITEGRAVIR FROM THEIR DEGRADATION PRODUCTS

, 2016
Objective: A simple, rapid, accurate and precise stability-indicating UPLC analytical method has been developed and validated for the quantitative analysis of Emtricitabine, Tenofovir, Cobicistat and Elvitegravir in bulk drugs and combined dosage forms ...
P., Prahlad, N., Ravindra, S. K., Mastanamma, Rao M., Venkata Basaveswara, P., Revathi Naga Lakshmi   +4 more
core  

Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non‐case study from the global pharmacovigilance database VigiBase®

Pharmacology Research & Perspectives
In 2018, a significant neural tube defects (NTD) signal was reported after pre‐conceptional exposure to dolutegravir, but was not confirmed in further analysis.
Laura Saint‐Lary, Isabelle Lacroix, Valériane Leroy, Agnès Sommet   +3 more
doaj   +1 more source

Elvitegravir [PDF]

, 2020
openaire   +1 more source

Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS

Patient Preference and Adherence, 2015
Roberta Prinapori,1 Antonio Di Biagio2 1Infectious Diseases, University of Genoa, Genoa, Italy; 2Unit of Infectious Diseases, IRCCS AOU San Martino-IST, Genoa, Italy Abstract: The fixed-dose combination (FDC) elvitegravir/cobicistat/emtricitabine ...
Prinapori R, Di Biagio A
doaj  

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

Drug Design, Development and Therapy, 2015
Christopher E Kandel,1 Sharon L Walmsley1,21Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Division of Infectious Diseases, University Health Network, Toronto, ON, CanadaAbstract: Dolutegravir is the newest integrase strand transfer
Kandel CE, Walmsley SL
doaj  

Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis. [PDF]

J Comp Eff Res
Curteis T, Eddowes LA, Karlsson A, Luedke H, Rubinstein M, Hempfling M, Gurney J, Gandhi-Patel B, Unger N, Mordi U, Chen M, Jarrett J, Sherman EM, Mounzer K, Khalsa AM, Dinges WL, McKellar MS, Lipps A.   +17 more
europepmc   +1 more source

Inter-day accuracy and precision of calibration standards (n>6) and quality control (QC) standards (n>6) of elvitegravir in human liver microsomes.

, 2016
Inter-day accuracy and precision of calibration standards (n>6) and quality control (QC) standards (n>6) of elvitegravir in human liver microsomes.
Mohammad A. Rahman (1806823), Chetan Rathi (1806826), Weihua Li (144468), Santosh Kumar (106550), Bernd Meibohm (110267), Junhao Li (844050), Narasimha M. Midde (309014)   +6 more
core  

Association between plasma concentrations of integrase strand transfer inhibitors and body weight gain in women with HIV. [PDF]

AIDS
Lahiri CD, Soibi-Harry AP, Musonge-Effoe J, Alvarez JA, Dumond JB, Mehta CC, Yang Q, Sheth AN, Ofotokun I, Sykes C, Hartauer M, Khoei A, Alcaide ML, Rubin LH, Konkle-Parker D, Floris-Moore M, Topper EF, French AL, Cocohoba J, Kassaye S, Augenbraun M, Sharma A, Tien PC.   +22 more
europepmc   +1 more source